Next, immunohistochemistry assay suggested that niraparib treatment intensified MEG3 and GATA6 expression and decreased miR-181-5p expression in tumor tissues, while MEG3 silencing abolished these effects (Figs. 7D–7F). This evidence concerns the gene GATA6 and neoplasm.